Last updated 31 days ago

Clinical Trial Evaluating Safety and Efficacy of Resomelagon on Dengue Infection (RESOVIR-2)

120 patients around the world

Available in Brazil

Federal University of Minas Gerais

120Patients around the world

This study is for people with

Dengue

Requirements for the patient

To 65 Years

All Gender

Medical requirements

: Patients who are 18 to 65 years old.
Able to understand study procedures and give informed consent.
Presents with more than 36 and less than 84h since symptoms onset.
Symptoms compatible with dengue infection (fever, myalgia, arthralgia, headache or conjunctivitis) with positive antigen test or polymerase chain reaction test.

: Has any comorbidity which is perceived as significant by the investigator.
Significant laboratory abnormalities discovered at triage: Hemoglobin <10g/dL; Platelet count < 50.000/microL; alanine transaminase > 3x upper limit of normal; Total bilirubin >1.5 x upper limit of normal; glomerular filtration rate < 60mls/min/1.73m2.
Contraindications or known hypersensitivity to Resomelagon.
Presents as dengue with warning signs or severe dengue at inclusion.
Currently participating in another drug clinical trial.
Clinical evidence of another infection that might explain current symptoms.
Pregnant women or women actively trying to achieve pregnancy.

StudyRESOVIR-2

SponsorFederal University of Minas Gerais

Study typeInterventional

Conditions

Dengue

Requirements

To 65 YearsAll Gender

Unique study IDclinicaltrials.gov

NCT06917001